Wells takes the role effective October 1, 2026 under a services agreement with Atlas Bookkeeping, LLC, and becomes the company's principal financial and accounting officer.
The June 2026 letter reports an eight-month heartworm study begun April 1, 2026, a FINRA application submitted June 12, 2026, and a collaboration paying approximately $15,000 to $18,000 a month.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $244,235.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Global Innovative Platforms
What is the ticker symbol of Global Innovative Platforms?
Global Innovative Platforms Inc. trades under the ticker GIPL on OTC.
Where is Global Innovative Platforms listed?
Global Innovative Platforms Inc. is listed on OTC.
Which country or territory is Global Innovative Platforms listed under?
Our directory records Global Innovative Platforms Inc. under United States.
Does aibio.space cover Global Innovative Platforms?
aibio.space lists Global Innovative Platforms Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Global Innovative Platforms's revenue last year?
$0 for the fiscal year ended Sep 30, 2025, as reported to the SEC.
Is Global Innovative Platforms profitable?
Global Innovative Platforms Inc. reported a net loss of $718,251 for the fiscal year ended Sep 30, 2025, and used $560,740 of cash in operations, per its annual report to the SEC.
How much does Global Innovative Platforms spend on research and development?
$382,832 in the fiscal year ended Sep 30, 2025, per its annual report.
How much cash does Global Innovative Platforms have?
$244,235 in cash at Jun 30, 2026, per its 10-Q.
What is the latest Global Innovative Platforms (GIPL) stock news?
Our latest story on Global Innovative Platforms, dated Oct 6, 2026: "Global Innovative Platforms appoints David R. Wells as fractional chief financial officer". Wells takes the role effective October 1, 2026 under a services agreement with Atlas Bookkeeping, LLC, and becomes the company's principal financial and accounting officer. Source.
How long will Global Innovative Platforms's cash last?
From our story of Jun 15, 2026: It refers shareholders to the 10-Q for the period ended March 31, 2026, which includes a discussion of liquidity and going concern considerations. Source.
How can I follow Global Innovative Platforms (GIPL) news?
Press Follow on this page to add Global Innovative Platforms to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Global Innovative Platforms so far, in Company Updates.
Investor discussion: Global Innovative Platforms
Members talk about Global Innovative Platforms (GIPL). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Global Innovative Platforms, newest first. Each line links the filing it comes from.
Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:GIPL on TradingView.
Listing details
Global Innovative Platforms Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker GIPL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Company
Global Innovative Platforms Inc.
Ticker
GIPL
Listing
OTC
Country or territory
United States
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio